Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 179 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Disease Risk Reduction Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

NCT01929083
View directory record Official record
Conditions
Prolonged QT Interval in EKG and Sudden Death
Interventions
Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study

NCT00926848
View directory record Official record
Conditions
Coronary Heart Disease, Cardiac Rehabilitation
Interventions
Partners Together in Health (PaTH) Intervention
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 20, 2026, 9:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure

NCT03480633
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Heart Failure, Right Sided, Heart Failure With Mid Range Ejection Fraction, Cardiovascular Risk Factor
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindful Hearts Study: Mindfulness to Reduce Stress

NCT01784796
View directory record Official record
Conditions
Cardiovascular Disease, Psychological Stress, Stroke, Coronary Artery Disease
Interventions
Mindfulness Based Stress Reduction, Health Education Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Automated Guidance Tool for Medical Encounters Addressing Therapeutic Lifestyle Changes (AuGMEnT).

NCT00790491
View directory record Official record
Conditions
Heart Disease, Diabetes
Interventions
guidance tool for providers for lifestyle changes
Behavioral
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 20, 2026, 9:56 AM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

NCT00615589
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Fludarabine/Busulfan x 4 days, stem cell transplant
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy

NCT00427193
View directory record Official record
Conditions
Aging
Interventions
Caloric Restriction (CR), Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 50 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 20, 2026, 9:56 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Beverly Hills, California • Irvine, California • Santa Rosa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

Heart Disease on the Mend

NCT00127751
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions
Enhance health lifestyle changes and medication compliance
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2005 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Clinic-delivered Physical Activity Referrals to Cancer Survivors

NCT05216380
View directory record Official record
Conditions
Cancer, Physical Inactivity
Interventions
ActivityLink
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 20, 2026, 9:56 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
205
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Active, not recruiting Not applicable Interventional

Cancer and Blood Pressure Management, CARISMA Study

NCT04467021
View directory record Official record
Conditions
Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
Best Practice, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
25
States / cities
Creve Coeur, Missouri • St Louis, Missouri • The Bronx, New York + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional Results available

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT00549757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
8,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
118
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Minority Health Through Biofeedback and Stress Reduction

NCT07172152
View directory record Official record
Conditions
Cardiovascular Disease Risk Reduction, Chronic Stress, Anxiety, Emotional Regulation, Hypertension Prevention, Health Disparities
Interventions
HRV Biofeedback Training
Behavioral
Lead sponsor
Amelia Saul, PhD, CTRS, BCB
Other
Eligibility
18 Years to 35 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 4 Interventional

A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke

NCT04126486
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Zio®XT Monitor
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
70 Years and older
Enrollment
11,931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Guntersville, Alabama • Montgomery, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 20, 2026, 9:56 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430
View directory record Official record
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 20, 2026, 9:56 AM EDT
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
270
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

Behavioral Weight Loss and Stigma Reduction

NCT03704064
View directory record Official record
Conditions
Obesity
Interventions
Stigma-Reduction Intervention, Behavioral Weight Loss (BWL)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional

CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact

NCT02246400
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Pre-diabetes, Type 2 Diabetes, Cardiovascular Disease
Interventions
eCMP
Behavioral
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Burlingame, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Improving Heart Health in Appalachia

NCT01884246
View directory record Official record
Conditions
Obesity, Hypertension, Hyperlipidemia, Depression
Interventions
Self-care CVD risk reduction, Referral to primary care provider for CVD risk management
Behavioral · Other
Lead sponsor
Debra Moser
Other
Eligibility
21 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

NCT01760655
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 4 Interventional

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

NCT00139555
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 20, 2026, 9:56 AM EDT